login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
BICARA THERAPEUTICS INC (BCAX) Stock News
USA
- NASDAQ:BCAX -
US0554771032
-
Common Stock
13.93
USD
-0.71 (-4.85%)
Last: 11/10/2025, 8:00:00 PM
13.93
USD
0 (0%)
After Hours:
11/10/2025, 8:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
BCAX Latest News, Press Relases and Analysis
All
Press Releases
21 hours ago - By: Bicara Therapeutics Inc.
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
21 hours ago - By: Bicara Therapeutics Inc.
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
a month ago - By: Bicara Therapeutics Inc.
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
a month ago - By: Bicara Therapeutics Inc.
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
a month ago - By: Benzinga
- Mentions:
XBI
ALDX
APLT
NGNE
4 Biotech Stocks Seeing Explosive Momentum Gains
3 months ago - By: Bicara Therapeutics Inc.
Bicara Therapeutics to Participate in Upcoming Investor Conferences
3 months ago - By: Bicara Therapeutics Inc.
Bicara Therapeutics to Participate in Upcoming Investor Conferences
3 months ago - By: Zacks Investment Research
Does Bicara Therapeutics Inc. (BCAX) Have the Potential to Rally 187.73% as Wall Street Analysts Expect?
3 months ago - By: Bicara Therapeutics Inc.
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
3 months ago - By: Bicara Therapeutics Inc.
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
5 months ago - By: Relay Therapeutics, Inc.
- Mentions:
RLAY
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
5 months ago - By: Benzinga
- Mentions:
BOLT
CLRB
MESO
CBUS
...
12 Health Care Stocks Moving In Wednesday's After-Market Session
5 months ago - By: Bicara Therapeutics Inc.
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
5 months ago - By: Bicara Therapeutics Inc.
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
5 months ago - By: Bicara Therapeutics Inc.
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
5 months ago - By: Bicara Therapeutics Inc.
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
6 months ago - By: Yahoo Finance
- Mentions:
NRXP
USB
JAKK
IVR
...
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network
6 months ago - By: Yahoo Finance
- Mentions:
MS
CPNG
TGT
CRM
...
Morgan Stanley Names Coupang (CPNG) Its New Top Pick, Lifts PT
6 months ago - By: Yahoo Finance
- Mentions:
MS
GMED
MDT
SE
...
Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update
6 months ago - By: Yahoo Finance
- Mentions:
MS
NIO
TSLA
RZB
...
Morgan Stanley Maintains Buy rating on NIO Inc (NIO)
6 months ago - By: Yahoo Finance
Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients
6 months ago - By: Investor's Business Daily
- Mentions:
MRUS
MRK
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
6 months ago - By: Bicara Therapeutics Inc.
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
6 months ago - By: Bicara Therapeutics Inc.
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
6 months ago - By: Bicara Therapeutics Inc.
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Please enable JavaScript to continue using this application.